• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Neurological consequences of COVID-19
Pharmacol Rep. 2022 Sep 30. doi: 10.1007/s43440-022-00424-6. Online ahead of print.ABSTRACTIn December 2019, cases of pneumonia caused by infection with the previously unknown severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to coronavirus disease 2019 (COVID-19), were identified. Typical manifestations of COVID-19 are fever, cough, fatigue and dyspnoea. Initially, it was thought that the mechanism of action of SARS-CoV-2 was only associated with respiratory tract invasion, but it was later revealed that the infection might involve many other organs and systems, including the central and peripheral ner...
Source: Pharmacological Reports - September 30, 2022 Category: Drugs & Pharmacology Authors: Waldemar Brola Maciej Wilski Source Type: research

Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations
CONCLUSION: Current clinical evidence shows that tenecteplase is not inferior to alteplase for the treatment of ischemic stroke and suggests that tenecteplase may have a superior safety profile. Furthermore, tenecteplase also has practical advantages in terms of its administration. This can potentially lead to a decrease in medication errors and improvement in door to thrombolytic time.PMID:35020806 | DOI:10.1093/ajhp/zxac010
Source: American Journal of Health-System Pharmacy : AJHP - January 12, 2022 Category: Drugs & Pharmacology Authors: Kirubel Hailu Chad Cannon Sarah Hayes Source Type: research

COVID-19 and the Cardiovascular System: Insights into Effects and Treatments
Can J Physiol Pharmacol. 2021 Sep 21. doi: 10.1139/cjpp-2021-0093. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19), an acute and highly transmissible infectious disease has reached a pandemic level since March 11, 2020 and continues to challenge the healthcare system worldwide. The pathogenesis of COVID-19 is a complex process involving mechanisms that suppress the host antiviral and innate immune response, while triggering marked activation of coagulation and hyperinflammation leading to cytokine storm in severe COVID-19. This review summarizes current evidence related to COVID-19-associated cardiovascul...
Source: Canadian Journal of Physiology and Pharmacology - September 21, 2021 Category: Drugs & Pharmacology Authors: Joey-Bahige Chammas Dylan Delaney Naim Chabaytah Sarah Abdulkarim Adel Schwertani Source Type: research

Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 infection is the cause of the ongoing global pandemic. Mortality from COVID-19 infection is particularly high in patients with cardiovascular diseases. In addition, COVID-19 patients with preexisting cardiovascular comorbidities have a higher risk of death. Main cardiovascular complications of COVID-19 are myocardial infarction, myocarditis, acute myocardial injury, arrhythmias, heart failure, stroke, and venous thromboembolism. Therapeutic interventions in terms of drugs for COVID-19 have many cardiac adverse effects. Here, we review the relative the...
Source: Frontiers in Pharmacology - August 25, 2021 Category: Drugs & Pharmacology Source Type: research

Development of pulmonary embolism in a nonhospitalized patient with COVID-19 who did not receive venous thromboembolism prophylaxis.
CONCLUSION: This case suggests that nonhospitalized patients with COVID-19 may be at higher risk for VTE than patients with other medical illnesses and warrants further research into the risk of VTE in outpatients with COVID-19. PMID: 32780839 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - August 10, 2020 Category: Drugs & Pharmacology Authors: Uppuluri EM, Shapiro NL Tags: Am J Health Syst Pharm Source Type: research